PET/CT of dementia

Katherine Zukotynski; Phillip H. Kuo; David Mikulis; Pedro Rosa-Neto; Antonio P. Strafella; Rathan M. Subramaniam; Sandra E. Black

doi:10.2214/AJR.18.19822

PET/CT of dementia

Katherine Zukotynski
, Phillip H. Kuo
, David Mikulis
, Pedro Rosa-Neto
, Antonio P. Strafella
, Rathan M. Subramaniam
, Sandra E. Black

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

OBJECTIVE. In this article, we review the literature on PET/CT in the management of dementia, present evidence for best clinical practices, and discuss recent advances in the field. CONCLUSION. Standard-of-care imaging for dementia includes CT and MRI, primarily for excluding vascular lesions or masses, detecting atrophy, and monitoring disease severity. PET/CT is a powerful functional modality that can differentiate dementia types and influence management. Fluorine-18-FDG PET/CT reveals the spatial pattern of glucose metabolism in the brain. More recently, radiotracers for PET have been developed that bind to amyloid protein, tau protein, and neuroinflammatory markers.

Original language	English (US)
Pages (from-to)	246-259
Number of pages	14
Journal	American Journal of Roentgenology
Volume	211
Issue number	2
DOIs	https://doi.org/10.2214/AJR.18.19822
State	Published - Aug 2018

Keywords

Amyloid
Dementia
Imaging
PET/CT
Tau

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.2214/AJR.18.19822

Cite this

@article{296bb68a42f049a7817f96b79ab61739,

title = "PET/CT of dementia",

abstract = "OBJECTIVE. In this article, we review the literature on PET/CT in the management of dementia, present evidence for best clinical practices, and discuss recent advances in the field. CONCLUSION. Standard-of-care imaging for dementia includes CT and MRI, primarily for excluding vascular lesions or masses, detecting atrophy, and monitoring disease severity. PET/CT is a powerful functional modality that can differentiate dementia types and influence management. Fluorine-18-FDG PET/CT reveals the spatial pattern of glucose metabolism in the brain. More recently, radiotracers for PET have been developed that bind to amyloid protein, tau protein, and neuroinflammatory markers.",

keywords = "Amyloid, Dementia, Imaging, PET/CT, Tau",

author = "Katherine Zukotynski and Kuo, \{Phillip H.\} and David Mikulis and Pedro Rosa-Neto and Strafella, \{Antonio P.\} and Subramaniam, \{Rathan M.\} and Black, \{Sandra E.\}",

note = "Publisher Copyright: {\textcopyright} American Roentgen Ray Society.",

year = "2018",

month = aug,

doi = "10.2214/AJR.18.19822",

language = "English (US)",

volume = "211",

pages = "246--259",

journal = "American Journal of Roentgenology",

issn = "0361-803X",

publisher = "American Roentgen Ray Society",

number = "2",

}

TY - JOUR

T1 - PET/CT of dementia

AU - Zukotynski, Katherine

AU - Kuo, Phillip H.

AU - Mikulis, David

AU - Rosa-Neto, Pedro

AU - Strafella, Antonio P.

AU - Subramaniam, Rathan M.

AU - Black, Sandra E.

N1 - Publisher Copyright: © American Roentgen Ray Society.

PY - 2018/8

Y1 - 2018/8

N2 - OBJECTIVE. In this article, we review the literature on PET/CT in the management of dementia, present evidence for best clinical practices, and discuss recent advances in the field. CONCLUSION. Standard-of-care imaging for dementia includes CT and MRI, primarily for excluding vascular lesions or masses, detecting atrophy, and monitoring disease severity. PET/CT is a powerful functional modality that can differentiate dementia types and influence management. Fluorine-18-FDG PET/CT reveals the spatial pattern of glucose metabolism in the brain. More recently, radiotracers for PET have been developed that bind to amyloid protein, tau protein, and neuroinflammatory markers.

AB - OBJECTIVE. In this article, we review the literature on PET/CT in the management of dementia, present evidence for best clinical practices, and discuss recent advances in the field. CONCLUSION. Standard-of-care imaging for dementia includes CT and MRI, primarily for excluding vascular lesions or masses, detecting atrophy, and monitoring disease severity. PET/CT is a powerful functional modality that can differentiate dementia types and influence management. Fluorine-18-FDG PET/CT reveals the spatial pattern of glucose metabolism in the brain. More recently, radiotracers for PET have been developed that bind to amyloid protein, tau protein, and neuroinflammatory markers.

KW - Amyloid

KW - Dementia

KW - Imaging

KW - PET/CT

KW - Tau

UR - https://www.scopus.com/pages/publications/85052405694

UR - https://www.scopus.com/pages/publications/85052405694#tab=citedBy

U2 - 10.2214/AJR.18.19822

DO - 10.2214/AJR.18.19822

M3 - Article

C2 - 29949415

AN - SCOPUS:85052405694

SN - 0361-803X

VL - 211

SP - 246

EP - 259

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

IS - 2

ER -

PET/CT of dementia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this